Compare EPR & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | IRTC |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.7B |
| IPO Year | 1997 | 2016 |
| Metric | EPR | IRTC |
|---|---|---|
| Price | $55.52 | $110.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $64.68 | ★ $176.14 |
| AVG Volume (30 Days) | ★ 788.1K | 499.1K |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 105.00 | 61.71 |
| EPS | ★ 1.53 | N/A |
| Revenue | $718,357,000.00 | ★ $747,138,000.00 |
| Revenue This Year | $9.58 | $18.70 |
| Revenue Next Year | $6.44 | $17.79 |
| P/E Ratio | $36.27 | ★ N/A |
| Revenue Growth | 2.91 | ★ 26.24 |
| 52 Week Low | $48.11 | $100.85 |
| 52 Week High | $64.97 | $210.01 |
| Indicator | EPR | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 27.87 | 47.45 |
| Support Level | $49.01 | $113.82 |
| Resistance Level | $56.03 | $117.56 |
| Average True Range (ATR) | 1.05 | 3.29 |
| MACD | -0.14 | 0.38 |
| Stochastic Oscillator | 0.00 | 66.54 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.